NCT04616560 2026-03-19
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
10 trialsNCT05744375 2026-03-12
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT06048718 2026-03-10
TUXEDO-4
MedSIR
Phase 2 Active not recruiting
NCT07069712 2026-03-10
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT06311214 2026-03-06
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06486883 2026-03-02
PONTIAC
MedSIR
Phase 2 Recruiting
NCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07428044 2026-02-23
HERCULES
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting